Vmbook Online ordering

Alcobra Ltd

I am not a stock trading expert, but I can provide some general information about Alcobra Ltd.

Alcobra Ltd was a clinical-stage pharmaceutical company focused on the development of medicines to treat cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD). The company was headquartered in Rehovot, Israel and its stock was listed on the NASDAQ stock exchange under the ticker symbol "ADHD."

Alcobra's lead product candidate was a proprietary extended-release formulation of methylphenidate, which is a commonly prescribed medication for the treatment of ADHD. The company was in the process of conducting Phase 3 clinical trials for this product when it ran into financial difficulties.

In August 2017, Alcobra announced that it was exploring strategic alternatives, including a sale of the company or its assets, due to its weak financial position. The company subsequently filed for Chapter 11 bankruptcy protection in the United States in November 2017 and its assets were sold to Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland Therapeutics Inc.

Therefore, Alcobra Ltd is no longer a publicly traded company.